Yergeau, Andrée; Alain, Louise; Pless, Robert; Robert, Yves
February 1996
CMAJ: Canadian Medical Association Journal;2/15/1996, Vol. 154 Issue 4, p503
Academic Journal
No abstract available.


Related Articles

  • Safety Data on Meningococcal Polysaccharide Vaccine from the Vaccine Adverse Event Reporting System. Ball, Robert; Braun, M. Miles; Mootrey, Gina T. // Clinical Infectious Diseases;5/1/2001, Vol. 32 Issue 9, p1273 

    Focuses on a study which summarized reports to the Vaccine Adverse Event Reporting System of adverse reactions after meningococcal polysaccharide vaccination in the United States. Information on meningococcal polysaccharide vaccines; Research methods; Commonly reported events; Serious events...

  • Vaccination: An Updated Analysis of the Health Risks - Part 3. Null, Gary; Feldman, Martin // Townsend Letter;Dec2007, Issue 293, p115 

    The article presents the third part of a series of article on the risks of rotavirus, meningococcal, and smallpox vaccines. According to the Association of American Physicians and Surgeons (AAPS), the RotaShield vaccine caused bowel intussusception. It is noted that the new meningococcal...

  • Meningococcal vaccine group C conjugate/MMR varicella zoster virus vaccine.  // Reactions Weekly;Aug2015, Vol. 1566 Issue 1, p151 

    An abstract of the article "Surveillance of adverse events following immunization with meningococcal group C conjugate vaccine: Tuscany, 2005-2012," by M. Levi and colleagues is presented.

  • Aşıların Yan Etkileri. Arısoy, Emin Sami // Journal of Pediatric Infection / Cocuk Enfeksiyon Dergisi;Sep2008 Supplement, Vol. 2, p76 

    Vaccines, although safe, may be associated with adverse events ranging in severity from mild to life threatening. Vaccine-related adverse events, however, are uncommon and typically mild. Vaccine components can cause local or systemic reactions, including anaphylaxis and urticaria, in some...

  • Update: Guillain-Barré Syndrome Among Recipients of Menactra Meningococcal Conjugate Vaccine -- United States, June 2005-September 2006. Woo, E. J.; Ball, R.; Braun, M.; Clark, T.; Messonnier, N. Rosenstein; Wharton, M.; Vellozzi, C.; Campbell, S.; Weintraub, E.; Davis, R. // MMWR: Morbidity & Mortality Weekly Report;10/20/2006, Vol. 55 Issue 41, p1120 

    The article presents an update on the possible association between Guillain-Barrae Syndrome (GBS) and receipt of meningococcal conjugate vaccine (MCV4). Eight confirmed cases of GBS within 6 weeks after MCV4 vaccination has been identified from March 2005 to February 2006. Nine additional GBS...

  • Meningococcal vaccine and Guillain Barré syndrome.  // WHO Drug Information;2006, Vol. 20 Issue 4, p247 

    The article informs that the U.S. Food and Drug Administration (FDA) and Centers for Disease Control ( CDC) have updated an October 2005 alert to consumers and health care providers regarding reports indicating possible association between Guillain-Barré Syndrome (GBS) and meningococcal...

  • Group A and C meningococcal vaccines.  // Weekly Epidemiological Record;9/10/99, Vol. 74 Issue 36, p297 

    Examines the efficacy of group A and C meningococcal vaccines in controlling epidemics of meningococcal meningitis. Causes of meningococcal meningitis and septicemia; Use of vaccines in large-scale immunization programs; Number of mortality associated with meningococcal diseases.

  • Hepatitis B vaccine.  // MMWR: Morbidity & Mortality Weekly Report;9/6/1996 Supplement RR-12, Vol. 45 Issue 35, p7 

    Presents recommendations concerning the adverse reactions to the hepatitis B vaccine. Statistics on vaccine-associated side effects and adverse events.

  • Vaccines and Guillain-Barré Syndrome. Haber, Penina; Sejvar, James; Mikaeloff, Yann; DeStefano, Frank // Drug Safety;2009, Vol. 32 Issue 4, p309 

    Guillain-Barré syndrome (GBS) is the leading cause of acute flaccid paralysis in developed countries and is characterized by various degrees of weakness, sensory abnormalities and autonomic dysfunction. Although th underlying aetiology and pathophysiology of GBS are not completely understood,...

  • Time of Hope for the Eventual Elimination of Meningococcal Strains A, C, Y, and W-135 in the United States. Zimmerman, Richard Kent // American Family Physician;11/15/2005, Vol. 72 Issue 10, p1978 

    Discusses the prevention of meningococcal disease through the administration of meningococcal vaccines. Complications of the disease; Limitations of a polysaccharide vaccine; Possible association between the meningococcal conjugate vaccine and Guillain-Barré syndrome.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics